Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Daniel R. Barnes(University of Cambridge), Hélène Schuster(Inserm), Banu Arun(The University of Texas Health Science Center at Houston), Wendy K. Chung(Oregon Health & Science University), Marie‐Agnès Collonge‐Rame(Centre Hospitalier Universitaire de Besançon), Amie Blanco(University of California, San Francisco), Goska Leslie(University of Cambridge), Trinidad Caldés(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Julian Adlard(Chapel Allerton Hospital), Kathleen Claes(Statistics Belgium), Joe Dennis(University of Cambridge), Jacopo Azzollini(Fondazione IRCCS Istituto Nazionale dei Tumori), Marinus J. Blok(Maastricht University), Chrystelle Colas(Institut Curie), Ian Campbell(The University of Sydney), Thea M. Mooij(The Netherlands Cancer Institute), Capucine Delnatte(Laboratoire de Génétique Cellulaire), Angela R. Bradbury(University of Pennsylvania), Daniel Barrowdale(University of Cambridge), Nasim Mavaddat(MRC Epidemiology Unit), Irene L. Andrulis(University of Toronto), Katarzyna Białkowska(International Hereditary Cancer Center), Javier Benı́tez(Spanish National Cancer Research Centre), Anikó Bozsik(National Institute of Oncology), Joan Brunet(Institut Català d'Ornitologia), Norbert Arnold(Christian-Albrechts-Universität zu Kiel), Rósa B. Barkardóttir(University of Iceland), Saundra S. Buys(University of Utah), Susanne E. Boonen(Roskilde Sygehus), Bernardo Bonanni(European Institute of Oncology), Matti A. Rookus(The Netherlands Cancer Institute), Judith Balmañà(Vall d'Hebron Hospital Universitari), Nadine Andrieu(Inserm), Munaza Ahmed(Great Ormond Street Hospital), Lise Lotte Christensen(Aarhus University Hospital), Pascaline Berthet(Centre François Baclesse), Sophie Giraud(Hospices Civils de Lyon), Kristiina Aittomäki(University of Helsinki), Lesley McGuffog(University of Cambridge), Christine Lasset(Centre National de la Recherche Scientifique), Åke Borg(Lund University), Emmanuelle Mouret‐Fourme(Université Paris Sciences et Lettres), Noura Mebirouk(Inserm), Carole Brewer(Royal Devon and Exeter Hospital), Véronique Mari(Centre Antoine Lacassagne), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Laurence Faivre(Centre Georges François Leclerc), Paul Brennan(Newcastle upon Tyne Hospitals NHS Foundation Trust)
Cited by 145
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k